Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group
Purpose To compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT). Methods This is a multicentre, retrospective comparative study of 92 eyes treated with ye...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508926586880000 |
|---|---|
| author | José A. Roca Lihteh Wu Jans Fromow-Guerra Francisco J. Rodríguez María H. Berrocal Sergio Rojas Luiz H. Lima Roberto Gallego‐Pinazo Jay Chhablani J. Fernando Arévalo David Lozano-Rechy Martín Serrano |
| author_browse | David Lozano-Rechy Francisco J. Rodríguez J. Fernando Arévalo Jans Fromow-Guerra Jay Chhablani José A. Roca Lihteh Wu Luiz H. Lima Martín Serrano María H. Berrocal Roberto Gallego‐Pinazo Sergio Rojas |
| author_facet | José A. Roca Lihteh Wu Jans Fromow-Guerra Francisco J. Rodríguez María H. Berrocal Sergio Rojas Luiz H. Lima Roberto Gallego‐Pinazo Jay Chhablani J. Fernando Arévalo David Lozano-Rechy Martín Serrano |
| author_sort | José A. Roca |
| collection | Producción científica |
| description | Purpose To compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT). Methods This is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m 2 ) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm. Results In the MP group, at 12 months of follow-up, the mean best corrected visual acuity (BCVA) improved from the logarithm of the minimum angle of resolution (logMAR) of 0.41±0.27 at baseline to 0.21±0.26 (P<0.0001), 48.9% (45/92) of eyes had an improvement of ≥3 lines of BCVA from baseline, 48.9% (45/92) of eyes remained within 2 lines of baseline BCVA, and only 2.2% (2/92) of eyes lost ≥3 lines of BCVA from baseline. In the PDT group, at 12 months of follow-up, the mean BCVA changed from logMAR of 0.50±0.34 at baseline to 0.47±0.34 (P=0.89), 19% (13/67) of eyes had an improvement of ≥3 lines of BCVA from baseline, 73% (49/67) of eyes remained within 2 lines of baseline BCVA, and 7% (5/67) of eyes lost ≥3 lines of BCVA from baseline. There were no adverse events attributable to the yellow MP laser treatment. One eye in the PDT group developed choroidal neovascularisation, which was treated with three intravitreal bevacizumab injections. Conclusions Both PDT and MP are effective in restoring the macular anatomy. In places where PDT is not available, yellow MP laser may be an adequate treatment alternative. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/928 |
| institution | UPeU |
| language | English |
| publishDate | 2018 |
| publishDateRange | 2018 |
| publishDateSort | 2018 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/9282026-10-30T16:14:59ZYellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) GroupJosé A. RocaLihteh WuJans Fromow-GuerraFrancisco J. RodríguezMaría H. BerrocalSergio RojasLuiz H. LimaRoberto Gallego‐PinazoJay ChhablaniJ. Fernando ArévaloDavid Lozano-RechyMartín SerranoVerteporfinMedicineOphthalmologyPhotodynamic therapyVisual acuitySerous fluidChoroidal neovascularizationInternal medicineOrganic chemistryChemistryVerteporfinMedicineOphthalmologyPhotodynamic therapyVisual acuitySerous fluidChoroidal neovascularizationInternal medicineVerteporfin administration & dosageVerteporfin administration & dosageVerteporfin administration & dosageAdultAdultAdultChronic DiseaseChronic DiseaseChronic DiseaseFemaleFemaleFemaleFluorescein AngiographyFluorescein AngiographyFluorescein AngiographyFollow-Up StudiesFollow-Up StudiesFollow-Up StudiesHumansHumansHumansIndocyanine Green administration & dosageIndocyanine Green administration & dosageIndocyanine Green administration & dosageMaleMaleMaleMiddle AgedMiddle AgedMiddle AgedPhotochemotherapy methodsPhotochemotherapy methodsPhotochemotherapy methodsRetrospective StudiesRetrospective StudiesRetrospective StudiesVisual Acuity physiologyVisual Acuity physiologyVisual Acuity physiologyTreatment OutcomeTreatment OutcomeTreatment OutcomePhotosensitizing Agents administration & dosagePhotosensitizing Agents administration & dosagePhotosensitizing Agents administration & dosageTomography, Optical CoherenceTomography, Optical CoherenceTomography, Optical CoherenceLaser Therapy methodsLaser Therapy methodsLaser Therapy methodsCentral Serous Chorioretinopathy drug therapyCentral Serous Chorioretinopathy drug therapyCentral Serous Chorioretinopathy drug therapyCentral Serous Chorioretinopathy physiopathologyCentral Serous Chorioretinopathy physiopathologyCentral Serous Chorioretinopathy physiopathologyCentral Serous Chorioretinopathy surgeryCentral Serous Chorioretinopathy surgeryCentral Serous Chorioretinopathy surgeryCentral Serous Chorioretinopathy therapyCentral Serous Chorioretinopathy therapyCentral Serous Chorioretinopathy therapyHealth Sciences Medicine Ophthalmology Retinal Diseases and TreatmentsHealth Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s SyndromeHealth Sciences Medicine Ophthalmology Glaucoma and retinal disordersPurpose To compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT). Methods This is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m 2 ) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm. Results In the MP group, at 12 months of follow-up, the mean best corrected visual acuity (BCVA) improved from the logarithm of the minimum angle of resolution (logMAR) of 0.41±0.27 at baseline to 0.21±0.26 (P<0.0001), 48.9% (45/92) of eyes had an improvement of ≥3 lines of BCVA from baseline, 48.9% (45/92) of eyes remained within 2 lines of baseline BCVA, and only 2.2% (2/92) of eyes lost ≥3 lines of BCVA from baseline. In the PDT group, at 12 months of follow-up, the mean BCVA changed from logMAR of 0.50±0.34 at baseline to 0.47±0.34 (P=0.89), 19% (13/67) of eyes had an improvement of ≥3 lines of BCVA from baseline, 73% (49/67) of eyes remained within 2 lines of baseline BCVA, and 7% (5/67) of eyes lost ≥3 lines of BCVA from baseline. There were no adverse events attributable to the yellow MP laser treatment. One eye in the PDT group developed choroidal neovascularisation, which was treated with three intravitreal bevacizumab injections. Conclusions Both PDT and MP are effective in restoring the macular anatomy. In places where PDT is not available, yellow MP laser may be an adequate treatment alternative.Articlehttps://pubmed.ncbi.nlm.nih.gov/29439089https://repository.urosario.edu.co/handle/10336/2361310.1136/bjophthalmol-2017-311291https://hdl.handle.net/20.500.15037/928W2786766502enBritish Journal of Ophthalmology0007-11611468-20792018-02-082026-06-13T09:40:43Z2026-06-13T09:40:43Z |
| spellingShingle | Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Organic chemistry Chemistry Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Verteporfin administration & dosage Verteporfin administration & dosage Verteporfin administration & dosage Adult Adult Adult Chronic Disease Chronic Disease Chronic Disease Female Female Female Fluorescein Angiography Fluorescein Angiography Fluorescein Angiography Follow-Up Studies Follow-Up Studies Follow-Up Studies Humans Humans Humans Indocyanine Green administration & dosage Indocyanine Green administration & dosage Indocyanine Green administration & dosage Male Male Male Middle Aged Middle Aged Middle Aged Photochemotherapy methods Photochemotherapy methods Photochemotherapy methods Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Treatment Outcome Treatment Outcome Treatment Outcome Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Laser Therapy methods Laser Therapy methods Laser Therapy methods Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Ophthalmology Glaucoma and retinal disorders José A. Roca Lihteh Wu Jans Fromow-Guerra Francisco J. Rodríguez María H. Berrocal Sergio Rojas Luiz H. Lima Roberto Gallego‐Pinazo Jay Chhablani J. Fernando Arévalo David Lozano-Rechy Martín Serrano Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title | Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title_full | Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title_fullStr | Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title_full_unstemmed | Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title_short | Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group |
| title_sort | yellow 577 nm micropulse laser versus half dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy results of the pan american collaborative retina study pacores group |
| topic | Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Organic chemistry Chemistry Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Verteporfin administration & dosage Verteporfin administration & dosage Verteporfin administration & dosage Adult Adult Adult Chronic Disease Chronic Disease Chronic Disease Female Female Female Fluorescein Angiography Fluorescein Angiography Fluorescein Angiography Follow-Up Studies Follow-Up Studies Follow-Up Studies Humans Humans Humans Indocyanine Green administration & dosage Indocyanine Green administration & dosage Indocyanine Green administration & dosage Male Male Male Middle Aged Middle Aged Middle Aged Photochemotherapy methods Photochemotherapy methods Photochemotherapy methods Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Treatment Outcome Treatment Outcome Treatment Outcome Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Laser Therapy methods Laser Therapy methods Laser Therapy methods Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Ophthalmology Glaucoma and retinal disorders |
| topic_facet | Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Organic chemistry Chemistry Verteporfin Medicine Ophthalmology Photodynamic therapy Visual acuity Serous fluid Choroidal neovascularization Internal medicine Verteporfin administration & dosage Verteporfin administration & dosage Verteporfin administration & dosage Adult Adult Adult Chronic Disease Chronic Disease Chronic Disease Female Female Female Fluorescein Angiography Fluorescein Angiography Fluorescein Angiography Follow-Up Studies Follow-Up Studies Follow-Up Studies Humans Humans Humans Indocyanine Green administration & dosage Indocyanine Green administration & dosage Indocyanine Green administration & dosage Male Male Male Middle Aged Middle Aged Middle Aged Photochemotherapy methods Photochemotherapy methods Photochemotherapy methods Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Treatment Outcome Treatment Outcome Treatment Outcome Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Photosensitizing Agents administration & dosage Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Laser Therapy methods Laser Therapy methods Laser Therapy methods Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy drug therapy Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy physiopathology Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy surgery Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Central Serous Chorioretinopathy therapy Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Ophthalmology Glaucoma and retinal disorders |
| url | https://pubmed.ncbi.nlm.nih.gov/29439089 https://repository.urosario.edu.co/handle/10336/23613 https://hdl.handle.net/20.500.15037/928 |
| work_keys_str_mv | AT josearoca yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT lihtehwu yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT jansfromowguerra yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT franciscojrodriguez yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT mariahberrocal yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT sergiorojas yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT luizhlima yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT robertogallegopinazo yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT jaychhablani yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT jfernandoarevalo yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT davidlozanorechy yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup AT martinserrano yellow577nmmicropulselaserversushalfdoseverteporfinphotodynamictherapyineyeswithchroniccentralserouschorioretinopathyresultsofthepanamericancollaborativeretinastudypacoresgroup |